DCF — DANA-FARBER CANCER INSTITUTE
Enterprise Value: $-1.7B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-1.7B
Enterprise Value
$-557.2M
PV of Cash Flows
$-1.1B
PV of Terminal Value
$-1.8B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $1.9B | $-87.3M | -4.0% | $-169.4M | $-154.0M |
| Year 2 | $2.0B | $-69.9M | -3.0% | $-154.5M | $-127.7M |
| Year 3 | $2.1B | $-51.5M | -2.0% | $-138.6M | $-104.1M |
| Year 4 | $2.1B | $-42.4M | -2.0% | $-132.1M | $-90.3M |
| Year 5 | $2.2B | $-38.2M | -2.0% | $-130.6M | $-81.1M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-1.7B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$1.9B
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.049999999867276566
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5